Abstract:Rationale: Poor β cell proliferation is one of the detrimental factors hindering islet cell replacement therapy for patients with diabetes. Smad3 is an important transcriptional factor of TGF-β signaling and has been shown to promote diabetes by inhibiting β cell proliferation. Therefore, we hypothesize that Smad3-deficient islets may be a novel cell replacement therapy for diabetes. Methods: We examined this hypothesis in streptozocin-induced type-1 diabetic mice and type-2 diabetic db/db mice by transplanting Smad3 knockout (KO) and wild type (WT) islets under the renal capsule, respectively. The effects of Smad3KO versus WT islet replacement therapy on diabetes and diabetic kidney injury were examined. In addition, RNA-seq was applied to identify the downstream target gene underlying Smad3-regulated β cell proliferation in Smad3KO-db/db versus Smad3WT-db/db mouse islets. Results: Compared to Smad3WT islet therapy, treatment with Smad3KO islets produced a much better therapeutic effect on both type-1 and type-2 diabetes by significantly lowering serum levels of blood glucose and HbA1c and protected against diabetic kidney injuries by preventing an increase in serum creatinine and the development of proteinuria, mesangial matrix expansion, and fibrosis. These were associated with a significant increase in grafted β cell proliferation and blood insulin levels, resulting in improved glucose intolerance. Mechanistically, RNA-seq revealed that compared with Smad3WT-db/db mouse islets, deletion of Smad3 from db/db mouse islets markedly upregulated E2F3, a pivotal regulator of cell cycle G1/S entry. Further studies found that Smad3 could bind to the promoter of E2F3, and thus inhibit β cell proliferation via an E2F3-dependent mechanism as silencing E2F3 abrogated the proliferative effect on Smad3KO β cells. Conclusion: Smad3-deficient islet replacement therapy can significantly improve both type-1 and type-2 diabetes and protect against diabetic kidney injury, which is mediated by a novel mechanism of E2F3-dependent β cell proliferation.

Recombinant Reg3β Protein Protects Against Streptozotocin-Induced Β-Cell Damage and Diabetes

Recombinant Reg3α Prevents Islet β-Cell Apoptosis and Promotes β-Cell Regeneration

Pancreatic islet-specific overexpression of Reg3β protein induced the expression of pro-islet genes and protected the mice against streptozotocin-induced diabetes mellitus.

Resveratrol Prevents Streptozotocin-Induced Diabetes by Inhibiting the Apoptosis of Pancreatic Β-Cell and the Cleavage of Poly (Adp-Ribose) Polymerase.

Dimorphic Autoantigenic and Protective Effects of Reg2 Peptide in the Treatment of Diabetic Β‐cell Loss

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Recombinant Reg3α Protein Protects Against Experimental Acute Pancreatitis in Mice

Recombinant Reg3 Alpha Protein Protects Against Experimental Acute Pancreatitis In Mice

Deteriorated high-fat diet-induced diabetes caused by pancreatic β-cell-specific overexpression of Reg3β gene in mice

Regenerating islet‐derived protein 3 gamma (Reg3g) ameliorates tacrolimus‐induced pancreatic β‐cell dysfunction in mice by restoring mitochondrial function

Regenerating islet-derived protein 3 gamma (Reg3g) ameliorates tacrolimus-induced pancreatic -cell dysfunction in mice by restoring mitochondrial function

Reg2 treatment is protective but the induced Reg2 autoantibody is destructive to the islets in NOD mice

Reg3g ameliorates Tacrolimus‐induced pancreatic β‐cell dysfunction by restoring mitochondrial function in murine models

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

Reversal of Streptozotocin-Induced Diabetes in Rats by Gene Therapy with Betacellulin and Pancreatic Duodenal Homeobox-1

Exocrine pancreas regeneration modifies original pancreas to alleviate diabetes in mouse models

P21cip-overexpression in the Mouse Beta Cells Leads to the Improved Recovery from Streptozotocin-Induced Diabetes.

Regenerating islet-derived protein 1 inhibits the activation of islet stellate cells isolated from diabetic mice.

Histone Deacetylase 3-Selective Inhibitor RGFP966 Ameliorates Impaired Glucose Tolerance Through Β-Cell Protection.

Smad3 deficiency improves islet-based therapy for diabetes and diabetic kidney injury by promoting β cell proliferation via the E2F3-dependent mechanism